1475 results about "Gut flora" patented technology

The invention relates to the technical field of medical informatics, and discloses an intestinal flora associated disease risk prediction system based on multi-data set difference mutual identification, and the system comprises the steps: capturing the dynamic evolution characteristics of a network through constructing a species-genus-phylum three-level microbial interaction network, and employing a time sequence diagram convolution network; and designing a network disturbance experiment, introducing a network recovery force index to quantify the network recovery capability, constructing a network vulnerability map to identify key nodes and analyze a disturbance propagation path, and integrating stable and consistent network toughness characteristics in multiple data sets to establish an early warning mechanism. By means of the method, early and accurate early warning of disease risks is achieved, and a key time window is provided for clinical intervention.

The invention relates to a weight-losing enzyme and a preparation method thereof, and belongs to the technical field of biology, and the weight-losing enzyme comprises a fruit enzyme, a vegetable enzyme, a seed enzyme and a lotus leaf extract; the fruit enzyme is obtained by performing enzymolysis on mixed fruit pulp of apples, lemons, grapefruits and haws through pectinase, performing enzymolysis through pepsase and performing co-fermentation through bifidobacterium longum and lactobacillus acidophilus; the vegetable enzyme is obtained by performing enzymolysis on mixed vegetable pulp of wax gourd pulp, celery and spinach through pectinase, performing enzymolysis through pepsin and performing fermentation through lactobacillus plantarum and bifidobacterium adolescentis; the seed enzyme is obtained by carrying out trypsin enzymolysis on mixed powder of semen raphani and phaseolus calcaratus, then carrying out nattokinase enzymolysis and then fermenting with bifidobacterium breve; the lotus leaf extract is obtained by sequentially carrying out enzymolysis on lotus leaves through hemicellulase, snail protease and nattokinase. All the components are matched for use, so that the weight-losing food has the effects of promoting digestion, inhibiting fat absorption, regulating intestinal flora, promoting metabolism and the like, and has a good weight-losing effect.

The invention provides application of polygonatum cyrtonema polysaccharide in preparation of medicines for treating ulcerative colitis or reducing blood glucose. A main chain of a sugar chain structure of the homogeneous polysaccharide PCP2 in polygonatum cyrtonema is mainly composed of-> 1)-beta-D-Fur-(2->,-> 1, 6)-beta-D-Fur-(2-> and-> 6)-alpha-D-Glcp-(1-> and beta-D-Fur-(2->), a side chain is mainly composed of beta-D-Fur-(2-> and-> 2)-beta-D-Fur-(6-> at a C-6 position of-> 1, 6)-beta-D-Fur-(2->), Fur represents furanose, Glcp represents glucopyranose, Glcp represents glucopyranose, and Glcp represents glucopyranose. The novel polysaccharide compound can relieve intestinal injury of mice, increase expression of tight nectin and mucoprotein, relieve oxidative stress reaction, promote production of short-chain fatty acid and improve composition of intestinal flora, and can be applied to the field of medicine as a medicine for treating ulcerative colitis. Meanwhile, the homogeneous polysaccharide PCP2 in polygonatum cyrtonema can significantly inhibit the activity of alpha-amylase and alpha-glucosidase, can also promote the ability of insulin resistance 3T3-L1 fat cells to uptake and consume glucose, shows a significant hypoglycemic effect, and has a good development prospect in the aspect of preparation of hypoglycemic drugs.

The invention belongs to the technical field of medical data processing and artificial intelligence, and particularly relates to a cardiovascular disease risk prediction system based on multi-modal fusion, which comprises a multi-modal data acquisition and preprocessing module, a cross-modal association graph construction module, a dynamic fusion and prediction module based on a graph neural network and an interpretability analysis module. By constructing a heterogeneous graph fusing prior knowledge and data driving and utilizing a graph attention network to perform multi-level dynamic feature fusion, deep integration and interaction of multi-modal data such as genomes, iconography, clinical and intestinal flora metabolism are realized, so that the accuracy and interpretability of cardiovascular disease risk prediction are improved.

The invention belongs to the field of new application of medicines, and particularly relates to gastrodia elata polysaccharide and application thereof. The gastrodia elata polysaccharide component GEP-2 is separated from crude gastrodia elata polysaccharide, structural characterization detection is conducted on the GEP-2, the result shows that the gastrodia elata polysaccharide GEP-2 is prepared from, by mass, 89.08% of glucose, 2.40% of galactose, 7.12% of galacturonic acid, 0.86% of arabinose and 0.54% of rhamnose, and the animal experiment result shows that the GEP-2 relieves the symptoms of mouse colitis, relieves weight loss and shortens the colon length; the traditional Chinese medicine composition has the advantages of reducing serum TNF-alpha, IL-1beta and IL-6 proinflammatory cytokine levels, improving the intestinal barrier function, reducing inflammatory cell infiltration, regulating the intestinal flora composition structure of mice and relieving ulcerative colitis.

The invention provides an animal bifidobacterium subsp. Lactis HNU329 with uric acid reducing ability and application thereof, the animal bifidobacterium subsp. Lactis HNU329 is preserved in Guangdong Microbiological Culture Collection Center GDMCC, the preservation address is Institute of Microbiology, Guangdong Academy of Sciences, on 5th floor, No. 59, No. 100 Courtyard, Xianlie Middle Road, Guangzhou, the preservation date is April 22, 2024, the preservation number is GDMCC No: 64546, and the preservation number is CGMCC No: 64546. The preparation method comprises the following steps of: classifying and naming Bifidobacteria animata subsp.lactis, and carrying out classification and naming on the Bifidobacteria animata subsp.lactis. The strain has good capacity of degrading nucleoside and purine in vitro, also shows good uric acid reducing capacity and anti-inflammatory capacity in animal model evaluation, and can regulate intestinal flora of mice with hyperuricemia and improve symptoms of hyperuricemia. The traditional Chinese medicine composition has no toxic or side effect, high safety and wide application prospect.

The invention relates to the technical field of biological information mining, in particular to a multi-omics data optimization method and system for intestinal flora matching and a medium. The method comprises the following steps: acquiring historical intestinal tract multi-omics data and integrating the historical intestinal tract multi-omics data to obtain host intestinal tract multi-omics data; performing multi-omics data fusion based on the host intestinal multi-omics data to obtain microbial flora fusion data; performing pattern classification according to the host intestinal tract multi-omics data to obtain host intestinal tract physiological pattern data; carrying out physiological pattern influence factor calculation on the microbial flora fusion data to obtain host intestinal tract physiological pattern influence factors; and performing host intestinal flora matching on the microbial flora fusion data and the host intestinal physiological data according to the host intestinal physiological pattern influence factor, thereby obtaining intestinal flora matching data. According to the method, the accuracy of flora matching prediction can be improved.

The invention relates to a method for identifying a disease microorganism-metabolite combined marker based on a host-flora co-metabolism model. The method comprises the following steps: processing microbiome data; setting diet constraint conditions; determining classification composition of intestinal microorganisms of each individual, mapping abundance of each microorganism to a human microorganism genome scale metabolism model, and constructing an individualized flora metabolism network model; carrying out metabolic flow simulation on the constructed flora metabolism network model; integrating the constructed flora metabolism network model with the host metabolism network model, and predicting the metabolic flow and metabolite change of the whole system; and establishing a disease classifier based on a random forest machine learning algorithm to identify the microorganism-metabolite combined marker. According to the method, the complex metabolic process between the human body and the intestinal flora is restored in a metabolic network modeling and metabolic flow simulation mode, the method has the non-invasive characteristic, the time and economic cost is remarkably reduced, and meanwhile, the method has a great advantage in accuracy.

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.

The invention discloses a multi-modal animal abnormal data behavior classification method and device which are applied to the technical field of data processing, and the method comprises the steps: obtaining abnormal data of a target animal in different development stages; the abnormal data comprises behavior video data and intestinal flora data of the same animal; performing feature extraction on the behavior video data to obtain behavior features representing animal action modes; analyzing the intestinal flora data to obtain intestinal flora characteristics; performing multi-modal data fusion on the behavior characteristics and the intestinal flora characteristics to generate fusion characteristics; inputting the fusion features into a pre-trained data model, classifying animal behaviors through the data model, and outputting a classification result; through the behavior-flora multi-modal fusion strategy, the classification accuracy is improved, and clues are provided for early intervention.

The invention discloses a method and system for predicting juvenile depression based on intestinal flora, and relates to the technical field of bioinformatics and artificial intelligence, and the method comprises the steps: firstly, obtaining an original sequence of a microbiome, carrying out the preprocessing of the original sequence of the microbiome, and obtaining a feature matrix; and screening core flora characteristics with stable trans-folding by adopting characteristic importance evaluation and interpretability analysis based on a gradient boosting decision tree. A mixed weighted graph is constructed based on Spearman correlation and a proximity relationship, and an absolute value of a correlation coefficient is taken as an edge weight and an edge density is adjusted through a threshold adaptive strategy. And finally, through an improved graph attention neural network, based on edge weight attention, layer normalization and random inactivation, enhancing robustness, and adopting adaptive optimization to complete parameter learning. And determining a dynamic classification threshold according to the AUC of the target patient, and outputting a sample discrimination result and confidence. According to the method, the accuracy, stability and biological interpretability of juvenile depression recognition are remarkably improved.

The invention relates to the technical field of feed products, in particular to a fatty acid composition and application thereof in preparation of products for improving intestinal health. The fatty acid composition comprises arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, butyric acid and lauric acid, or a precursor substance capable of releasing the fatty acid in the digestive tract, and the mass of the fatty acid composition is calculated according to the mass of the arachidonic acid, the mass of the docosahexaenoic acid, the mass of the eicosapentaenoic acid, the mass of the butyric acid and the mass of the lauric acid. The additive is prepared from the following components in parts by weight: 7-10 parts of arachidonic acid, 3-7 parts of docosahexaenoic acid, 3-7 parts of eicosapentaenoic acid, 2-5 parts of butyric acid and 1-3 parts of lauric acid. The composition can effectively relieve inflammation and diarrhea, regulate intestinal flora and improve intestinal health, and drug resistance is not prone to being generated.

The invention belongs to the technical field of intestinal flora transplantation, and discloses an intestinal flora enrichment microsphere as well as a preparation method and application thereof and an enrichment method of intestinal flora. The intestinal flora enrichment microsphere provided by the invention specifically comprises a calcium alginate gel substrate and a porous adsorbent doped on the calcium alginate gel substrate, and the intestinal flora-enriched microspheres have a special pore size distribution situation, namely the pore size is gradually increased along the direction from the center to the outer layer. When the intestinal flora enrichment microspheres are applied to enrichment of intestinal flora, active flora cells can be effectively separated from small impurities such as intestinal contents and flora metabolites while the proportion of the high-activity flora cells is kept, and the intestinal flora enrichment microspheres have an excellent intestinal flora enrichment effect.

The invention belongs to the technical field of biological medicines, and particularly relates to a plant lactobacillus YYY01 strain and application thereof in anti-inflammation and production of gamma-aminobutyric acid. The preservation number of the plant lactobacillus YYY01 provided by the invention is GDMCC (China General Microbiological Culture Collection Center) NO: 65147. The plant lactobacillus YYY01 has relatively good biological safety, relatively good survival in a gastrointestinal tract environment and certain intestinal tract adhesion capacity; the plant lactobacillus YYY01 can produce gamma-aminobutyric acid at high yield, and has the effects of resisting inflammation, regulating intestinal flora and enhancing immune barrier. Good application prospects are shown in the aspects of improving the yield of gamma-aminobutyric acid and preparing products containing gamma-aminobutyric acid.

According to the probiotic agent for enhancing the immunity and improving the intestinal flora and the application of the probiotic agent, five specific different types of bifidobacterium strains are compounded, potential interaction exists among the five strains, and the five strains can cooperate with one another, so that the effect of enhancing the immunity and improving the intestinal flora is achieved. The bifidobacteria has the advantages that the bifidobacteria has synergistic interaction in the aspects of promoting the growth of immune organs and increasing the total quantity and diversity of intestinal flora, the bifidobacteria is matched with basic fermentation strains for yogurt fermentation, meanwhile, the composite prebiotics are added for synergistic yogurt fermentation, the quantity of the bifidobacteria at the end of a shelf life after the yogurt fermentation is finished is still not less than 1 * 10 < 8 > CFU / mL or 1 * 10 < 8 > CFU / g, and the content of the bifidobacteria is not less than the stability of lactic acid bacteria in the yoghourt is remarkably improved, so that the number of viable bacteria which enter the intestinal tract of a human body and play roles is remarkably increased, and the yoghourt has relatively good tolerance in the intestinal tract; the prepared yoghurt is fine and smooth in texture, rich in taste and rich in fragrance; in addition, the immune decline and intestinal flora disorder caused by cyclophosphamide (CTX) can be remarkably improved, and a positive effect on immunological enhancement is achieved.

The invention relates to the technical field of microorganisms, and particularly discloses a fermentation method of bifidobacterium longum BBMN68 as well as a fermented product, a postbiotic and application of the fermented product. According to the method for fermenting the bifidobacterium longum BBMN68, a fermentation substrate comprises alkaline protease hydrolyzed milk and a pomelo peel extract; the hydrolysis rate of the alkaline protease hydrolyzed milk is 9-11%, and the water-soluble dietary fiber content of the shaddock peel extract is 75-80%; the mass ratio of the alkaline protease hydrolyzed milk to the shaddock peel extract is (10-15): (1-3). The content of active ingredients in the fermented product prepared by the method is high, and after the fermented product is prepared into the postbiotics to be taken, the immune function of an organism can be recovered, immune organ damage is reduced, inflammation is relieved, and intestinal flora is regulated and controlled.

The invention discloses an intestinal flora marker related to juvenile depression, a product and application of the intestinal flora marker. The intestinal flora marker is prepared from any one or more of prokaryotic streptococcus parahaemolyticus, streptococcus salivarius, Alistipep and Lacnospiraceae, and the intestinal flora marker is prepared from any one or more of prokaryotic streptococcus parahaemolyticus, streptococcus salivarius, Alistipep and Lacnospiraceae, and the intestinal flora marker is prepared from any one or more of the prokaryotic streptococcus parahaemolyticus, the streptococcus salivarius, the Alistipep and the Lacnospiraceae, the prokaryotic streptococcus parahaemolyticus, the Streptococcus salivarius, the Alistipep and the Lacnospiraceae. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the intestinal flora marker. The invention provides a product for diagnosing juvenile depression and a computer program product related to the juvenile depression. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of depression of teenagers, and provides a new tool for clinical diagnosis.

The invention relates to ackermania muciniphila Akk21 with hypoglycemic capacity and application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides an ackermania muciniphila strain Akk21 with a blood sugar reducing capability. The preservation number of the ackermania muciniphila strain Akk21 is CCTCC (China Center for Type Culture Collection) NO: M 20242779. The invention also provides hypoglycemic drugs, functional food for promoting lead excretion, health care products and a method for preventing and treating lead / arsenic pollution based on the strain Akk21. The Ackermania muciniphila Akk21 has excellent lead and arsenic tolerance and hypoglycemic capacity, can effectively reduce the blood lipid level of mice with type II diabetes, has a remarkable reduction effect on inflammation of the whole body of the mice, and can remarkably reduce the number of harmful flora in the intestinal tract by increasing the abundance of effective flora in the intestinal tract, so that the content of the harmful flora in the intestinal tract is reduced, and the content of the harmful flora in the intestinal tract is reduced. The species diversity and abundance of intestinal flora are improved.

The invention discloses lactobacillus reuteri LR69 capable of enhancing a gastric mucosal barrier and application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides a lactobacillus reuteri LR69, and the preservation number of the lactobacillus reuteri LR69 is CGMCC (China General Microbiological Culture Collection Center) No.33731. The lactobacillus reuteri LR69 is a lactobacillus reuteri LR69. The invention also provides application of the strain in preparation of food with an auxiliary protection function on gastric mucosa, and / or food with an intestinal flora regulating function, and / or a product for relieving gastritis, and / or food with an immunity enhancing function, and / or a bacteriostatic agent. The invention further discloses a food with an auxiliary protection function on gastric mucosa, a food with an intestinal flora regulating function, a product for relieving gastritis, a food with an immunity enhancing function, a bacteriostatic agent and an in-vitro bacteriostasis method based on the strain. The lactobacillus reuteri LR69 disclosed by the invention can effectively assist in protecting gastric mucosa, regulating intestinal flora, relieving gastritis, enhancing immunity and realizing broad-spectrum bacteriostasis.

The invention relates to 2 '-fucosyllactose, in particular to application of the 2'-fucosyllactose to preparation of immune balance drugs or food. The immune balance comprises regulation and control of the ratio of Th17 cells to Treg cells of Th17 / Treg immune imbalance offspring activated by maternal immune or induced by virus infection; according to the application disclosed by the invention, the fact that filial generations generated after the maternal body of a mammal generates immune reaction activation can regulate and control the proportion of Th17 and Treg cells through the influence of 2 '-fucosyllactose on intestinal flora is found, so that Th17 and Treg immune balance is realized; in addition, social and cognitive disorders and repetitive behaviors related to filial generation autism induced by Th17 / Treg immune imbalance can be improved.

The invention discloses application of lactobacillus rhamnosus in preparation of a preparation for relieving allergic rhinitis. The invention provides application of the lactobacillus rhamnosus OF44-15Ph10T or a composition containing the lactobacillus rhamnosus OF44-15Ph10T in preparation of a product with at least one of the following functions: preventing and / or treating allergic rhinitis; the symptoms of allergic rhinitis are improved or relieved; the nasal mucosa injury caused by allergic rhinitis is repaired; intestinal pathogens are inhibited; the intestinal flora balance is regulated; the lactobacillus rhamnosus OF44-15Ph10T provided by the invention provides a new direction for treating allergic rhinitis, can be applied to the fields of food, health care products and medicines, and has a wide industrial prospect.

The invention discloses a medicinal and edible homologous compound based on probiotic fermentation synergy and application of the medicinal and edible homologous compound in blood sugar regulation and control, and belongs to the technical field of microorganisms and fermentation engineering. The preparation method comprises the following steps: respectively carrying out two-stage fermentation on aloe, mulberry leaves and liquorice by utilizing saccharomyces cerevisiae BLCC4-0032 and plant lactobacillus DFR-1, so as to obtain a fermentation mixture; the preparation method comprises the following steps: fermenting a fermentation mixture, adding balsam pear peptide into the fermentation mixture to obtain a medicinal and edible compound, forming a metabolic closed loop, and cooperatively regulating a'blood sugar-liver-intestinal flora axis', thereby providing a new solution for diabetes intervention, and opening up a new path for preventing non-alcoholic fatty liver and intestinal inflammation caused by glucose and lipid metabolism disorder.

The invention discloses a capsule robot for collecting intestinal flora and a control method of the capsule robot. The capsule robot comprises a capsule robot body and a rotatable collecting module installed in the capsule robot body. A collecting port is formed in the capsule robot body, a plurality of collecting cabins are formed in the rotating face of the collecting module, and the collecting module rotates to enable the collecting cabins to be communicated with or not communicated with the collecting port. The capsule robot is small in size and capable of achieving the flora sampling function at the same time, all the assemblies are compactly integrated in the capsule robot, the cross contamination problem between different detection parts and different collection cabins is avoided through structural design and certain sealing treatment, a control circuit is a small-size control panel, and the control circuit is simple in structure and convenient to operate. According to the capsule robot, circuit layout and space utilization are optimized, the size is reduced, meanwhile, functional integrity is guaranteed, remote non-contact collection in the body of a patient can be achieved through Bluetooth communication wireless control, and the capsule robot has the long-acting power management capacity.

The invention discloses bifidobacterium longum subsp.infantis capable of promoting bone growth and a metagen thereof, and belongs to the technical field of biology. The bifidobacterium longum subsp. Infantis CCFM1445 provided by the invention can promote the increase of bone volume fraction, femoral bone trabecula thickness and far-end growth plate thickness of mammals in a growth period, reduce the levels of serum bone resorption markers I-type collagen amino-terminal peptide and tartrate-resistant acid phosphatase, improve the levels of serum bone alkaline phosphatase and parathyroid hormone, and improve the clinical application value of the bifidobacterium longum subsp. Infantis CCFM1445. And the relative abundance of the other bacteria in the intestinal flora and the levels of creatine and indole-3-lactic acid are increased. The thermally inactivated bifidobacterium longum subsp. Infantis CCFM1445 can promote the increase of the volume fraction of femoral bones and the number of bone trabecula of malnourished mice and improve the N-terminal propeptide level of serum I-type procollagen. Therefore, the medicine or health care product prepared from the bifidobacterium longum subsp. Infantis CCFM1445 can be used for assisting in regulating bone metabolism and bone mass, and has a wide market prospect.

The invention belongs to the technical field of biological medicine, and relates to application of galangal polysaccharide in preparation of a preparation for improving intestinal flora imbalance. The galangal polysaccharide provided by the invention can effectively improve the alteration of intestinal flora, especially improve the alteration of intestinal flora induced by hyperuricemia, the hyperuricemia can cause intestinal barrier injury, then the intestinal flora is translocated to induce the alteration of the intestinal flora, and the galangal polysaccharide can up-regulate Occludin and ZO-1, repair the intestinal barrier injury and improve the integrity of the intestinal tract; after the action of the galangal polysaccharide, the influence on the intra-group diversity Beta diversity of the flora is large, the flora structure deviation caused by hypeluricemia can be reversed, and the intestinal flora structure deviation can be relieved. The galangal polysaccharide provided by the invention is a potential novel prebiotic, has an excellent effect in improving intestinal flora imbalance, and has a good application prospect.

The utility model discloses a separation and concentration device for intestinal flora, which belongs to the technical field of biological extraction and comprises a flora extraction device and a negative pressure drainage apparatus, the flora extraction device is sequentially connected with a plurality of filters from top to bottom, and every two adjacent filters are detachably connected. The mesh size of the screen of each stage of filter is gradually reduced from the uppermost stage to the lower stage, the lowermost stage of filter is used for enriching and concentrating the intestinal flora suspension separated by the previous stage of filter, and the negative pressure drainage device is connected with the lowermost stage of filter and is used for collecting liquid generated in the enriching and concentrating process of the lowermost stage of filter; according to the separation and concentration device, the homogenizing device, the multi-stage filtering device and the enrichment and concentration device are integrated into a whole, the flora separation and concentration process is simplified, and the extraction efficiency of intestinal flora is improved.

The invention belongs to the technical field of biology, and particularly relates to a composition containing plant-derived exosomes as well as a preparation method and application of the composition. The invention provides a composition containing plant-derived exosomes. The composition is prepared from the following components in parts by mass: 1-60 parts of a plant-derived exosome preparation, 1-60 parts of chitosan oligosaccharide and 1-60 parts of probiotics. According to the composition provided by the invention, the plant-derived exosome, the probiotics and the chitosan oligosaccharide are compounded according to a specific proportion, so that the abundance of effective flora can be increased for a long time, the composition of intestinal flora can be improved, the structural balance of the intestinal flora can be regulated and maintained, the intestinal inflammation can be remarkably inhibited, the intestinal leakage can be improved, and the oxidative stress can be resisted; the repair of damaged intestinal mucosa and the elimination of inflammation are facilitated. The composition is safe and stable in raw materials, free of toxic and side effects and capable of being taken as daily diet.

The preparation method comprises the following steps: centrifuging an activated culture solution of animal bifidobacterium subsp. Lactis HNU212 to remove a supernatant, washing with 0.9% normal saline, adjusting the strain concentration to 1 * 10 < 9 > CFU / mL, and inactivating at 90 DEG C for 15 minutes, thereby obtaining the thermal inactivation bifidobacterium subsp. Lactis metagen. The invention also provides a preparation method of the thermal inactivation bifidobacterium subsp. Lactis metagen, and the preparation method of the thermal inactivation bifidobacterium subsp. Lactis metagen comprises the following steps of: preparing the thermal inactivation bifidobacterium subsp. Lactis metagen and the preparation method of the thermal inactivation bifidobacterium subsp. Lactis metagen. When applied to an HUA animal model, the thermal inactivation substance bifidobacterium subsp. Lactis metaplasm prepared by the invention can effectively reduce the serum uric acid level, relieve kidney and intestinal injury and regulate host intestinal flora, and has the effect of relieving and treating HUA.

The present invention belongs to the technical field of intestinal flora transplantation, and discloses an intestinal flora preparation, preparation method and application, and a method for detecting spore content. In the preparation method provided by the present invention, a human bacterial suspension obtained by purifying a fecal sample is treated by combining a slow heating pretreatment, a high temperature incubation treatment with a volatile ethanol solution, and a density gradient centrifugation method, which can effectively increase the spore yield and the germination rate of the obtained spores, while effectively removing harmful metabolites, viruses and other substances, thereby obtaining an intestinal flora preparation with high purity and high activity.

The present invention discloses a Bifidobacterium breve strain capable of clearing toxins in the body and its postbiotics, belonging to the technical field of microbial applications. The present invention isolates a Bifidobacterium breve strain ( Bifidobacterium breve ) WZA-BB07 from human feces, and its biological deposit number is: CCTCC NO: M20241530. The strain WZA-BB07 has good effects in degrading endotoxin and enterotoxin. The strain and Lactobacillus mucosae are mixed and fermented to prepare postbiotics. Bifidobacterium breve mainly improves the balance of intestinal flora and inhibits the growth of harmful bacteria. Lactobacillus mucosae helps repair the intestinal barrier through its metabolites during fermentation, enhancing the metabolism and clearance of toxins; extracts of Dendrobium officinale, Lonicera japonica, and Pueraria lobata are added to the fermentation medium, which not only provides rich nutrition for fermentation but also exerts the antioxidant, anti-inflammatory, and intestinal repair-promoting effects of ingredients with both medicinal and edible properties, further enhancing the detoxification ability and overall health effects of the postbiotic product.